
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
This trial is looking at AZD5069 and durvalumab for the most common type of liver cancer called hepatocellular carcinoma (HCC).
It is for people who can’t have surgery to remove the cancer because it has spread. This is .
Cancer Research UK supports this trial.
Doctors are looking for new treatments for people with liver cancer who can’t have surgery. In this trial they are looking at a new drug called AZD5069 in combination with another drug called durvalumab.
Durvalumab is a type of immunotherapy. It stimulates the body's to fight cancer cells. It is already a treatment for some other types of cancer.
AZD5069 is a new type of . It blocks a protein called CXCR2 which stops the cancer growing. Researchers think that having AZD5069 with durvalumab might help to control the cancer for longer.
The main aims of the trial are to:
The following bullet points are a summary of the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply.
Who can’t take part
Cancer related
You cannot join this trial if any of these apply. You:
Medical conditions
You cannot join this trial if any of these apply. You:
Other
You cannot join this trial if any of these apply. You:
This phase1/2 trial is taking place in the UK. The team need about 50 people to take part in total.
This trial is in 2 parts:
Dose escalation (part 1)
In this part, researchers want to find the best dose of AZD5069. Everyone has AZD5069 and durvalumab. The first few people have a low dose of AZD5069. If they don’t have any side effects the next few people have a higher dose. And so on, until they find the best dose to give. This is a dose escalation study.
Dose escalation (part 2)
Part 2 starts when they have found the best dose in part 1. In this part the researchers want to test the best dose of AZD5059 in combination with durvalumab in more people.
Trial treatment and how you have it
AZD5069 is a tablet. You take it twice a day, every day. The number of tablets and dose you take depends on when you join the trial.
You have durvalumab as a drip into a vein. You have it once every 4 weeks. It takes about 60 minutes each time.
You continue to have treatment for up to 2 years as long as it is helping you and the side effects aren’t too bad.
You stop treatment if your cancer gets worse. The trial team will talk to you about other treatment options.
Blood and tissue samples
The researchers ask you to give some extra tissue samples. They also ask to take some extra blood samples. Where possible, you have these at the same time as your routine blood tests.
They plan to use the samples to:
You need to agree to give all the samples to take part in the trial.
Diary
The team will give you a diary for you to complete during treatment. You write down the side effects you have and any medications you take.
You need to bring the diary with you every time you go into hospital.
You see a doctor and have some tests before taking part. These include:
You have durvalumab at the hospital on the day care ward. People in the first part of the trial have a few long hospital visits. These can take up to 12 hours so you might need to stay overnight. The team can tell you more about these visits and what they involve.
You shouldn’t need to stay overnight if you join the second part of the trial.
You see the doctor for a check up and blood tests:
You have a CT scan or an MRI scan every:
You stop having these trial scans if your cancer gets worse.
When you finish treatment you see the doctor 1 month later for a check up. After this, the trial team contact you every 3 months to see how you are. They may call you or see you at a routine hospital appointment.
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
Durvalumab can affect the ![]() ![]() If you have any of these side effects tell your doctor or nurse as soon as possible. You should tell them that you are on or have been on an immunotherapy. |
The most common side effects of durvalumab include:
Only a few hundred people have had AZD5069 so there may be side effects we don’t know about yet. So far, the most common side effects of AZD5069 include:
We have more information about durvalumab.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Jeff Evans
Cancer Research UK
Cancer Research UK Clinical Trials Unit, Glasgow
NHS Greater Glasgow and Clyde
University of Glasgow
This is Cancer Research UK trial number CRUK/19/014.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.